COMPOUNDS / PEPTIDE / MGF
PEPTIDE

MGF

MEDIUM RISK
BEST FOR:Recovery●●●●●●○○○○6/10
MGF · MECHANO-GROWTH FACTOR · MGF-C25E · IGF-1EC · IGF-1 SPLICE VARIANT E-PEPTIDE · MECHANO GROWTH FACTOR E PEPTIDE
PeptideRecoveryIGF-1Muscle RepairResearch Chemical

Mechano-growth factor, an IGF-1 splice variant peptide that promotes muscle and tissue repair in response to mechanical load.

ROUTE / DOSAGE
LOW200mcg
STANDARD300-400mcg
HIGH600mcg
Note: Inject bilaterally into trained muscle group post-workout for site-specific effect
CYCLE
2-4 weeks 2-3x per week post-workout followed by equal time off
BIOAVAILABILITY
low oral (~0%) ~100% subq/im
ACTIVE DURATION
1-2h (subjective)
STORAGE
Lyophilized powder: -20°C freezer. Reconstituted with bacteriostatic water: refrigerated 2-8°C stable 2-4 weeks. Protect from light.
HALF-LIFE
5-10min (plasma)
DURATION BREAKDOWN
Total2-4 hours
Onset15-30min
Come up15-30min
Peak30-60min
Offset1-2h
After effects12-24h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Satellite cell activation
Accelerated muscle repair
Enhanced tendon and ligament healing
Anti-apoptotic protection of stressed cells
Increased MMP-2 activity for tissue remodeling
Local site-specific anabolic response
§ 02 — RISKS
No human clinical safety data exists; all evidence is preclinical
Potential for unregulated research-grade peptide contamination
Hypoglycemia risk due to IGF-1 pathway activation
Injection site reactions and infection risk from non-sterile preparation
Unknown long-term effects on tissue homeostasis and cancer risk
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

MGF was identified as a locally produced growth factor splice variant that responds to mechanical stimulation in muscle tissue. In vitro studies demonstrate that synthetic MGF-C25E promotes tenocyte invasion via MMP-2 activity through the FAK-ERK1/2 pathway, and enhances periodontal ligament remodeling through Fyn-FAK kinases and MAPK signaling. Evidence is primarily preclinical, with no human clinical trials establishing efficacy or safety. The extremely short half-life of native MGF (minutes) limits practical therapeutic utility, leading to development of PEGylated variants. Research is limited to cell culture and animal models, with no established dosing protocols in humans.

§ 06 — SOURCES
[1]
Mechanochemical coupling of MGF mediates periodontal regeneration
pubmed.ncbi.nlm.nih.gov ↗
[2]
MGF enhances tenocyte invasion through MMP-2 activity via the FAK-ERK1/2 pathway
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT